Myriad Genetics
OverviewSuggest Edit
Myriad Genetics is a molecular diagnostic company which focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The Company offers molecular diagnostic tests, including DNA sequencing tests for hereditary breast, ovarian, colorectal and uterine cancer, a protein quantification test for assessing the disease activity of rheumatoid arthritis, RNA expression tests for assessing the aggressiveness of prostate cancer, diagnosing melanoma, and a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients. It also provides biomarker discovery, and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries, and operates an internal medicine emergency hospital primarily for internal medicine and hemodialysis.
| Type | Public | |
| Founded | 1991 | |
| HQ | Salt Lake City, UT, US | Map |
| Website | myriad.com | |
| Employee Ratings | More | |
| Overall Culture | B | More |
Recent NewsAll News
- Myriad Genetics CEO Paul J. Diaz to Present at Goldman Sachs 2021 Virtual Global Healthcare Conference
- Myriad Genetics Completes the Sale of Myriad myPath® Melanoma, LLC, Laboratory to Castle Biosciences
- Myriad Genetics Signs Definitive Agreement to Sell Myriad RBM to Q2 Solutions
- Myriad Genetics Appoints Melissa Gonzales to Lead Women’s Health Business
Key People/Management at Myriad Genetics
Bryan Riggsbee
Interim President and CEO, Chief Financial Officer
Paul J. Diaz
President and CEO
Patrick Burke
Executive Vice President, Emerging Products
Raymond Francot
Executive Vice President, International Operations
Bryan Dechairo
Officer, Executive Vice President, Development
Clivetty Martinez
Chief Compliance Officer
Myriad Genetics Office Locations
Myriad Genetics has offices in Salt Lake City, Austin, South San Francisco, Issy-les-Moulineaux and in 8 other locations
Salt Lake City, UT, US (HQ)
320 Wakara Way
Austin, TX, US
3300 Duval Rd
South San Francisco, CA, US
180 Kimball Way
South San Francisco, CA, US
341 Oyster Point Blvd
Issy-les-Moulineaux, FR
41 Rue Camille Desmoulins
Martinsried, DE
Bunsenstrasse 7
Myriad Genetics Financials and Metrics
Myriad Genetics Revenue
Myriad Genetics's revenue was reported to be $299.8 m in FY, 2020
| USD | |
|---|---|
Revenue (Q1, 2021) | 173.1m |
Net income (Q1, 2021) | (39.5m) |
EBIT (Q1, 2021) | (46.7m) |
Market capitalization (7-Jun-2021) | 2.3b |
Closing stock price (7-Jun-2021) | 29.3 |
Cash (31-Mar-2021) | 148.9m |
EV | 2.3b |
Myriad Genetics's current market capitalization is $2.3 b.
Annual
Quarterly
| USD | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 190.2m | 194.0m | 193.5m | 202.3m | 216.8m | 216.6m | 186.3m | 195.1m | 173.1m | |
Cost of goods sold | 43.0m | 44.4m | 44.1m | 49.7m | 52.1m | 48.6m | 49.7m | 49.6m | ||
Gross profit | 147.2m | 149.6m | 149.4m | 152.6m | 164.7m | 168.0m | 136.6m | 145.5m | ||
Gross profit Margin, % | 77% | 77% | 77% | 75% | 76% | 78% | 73% | 75% |
Annual
Quarterly
| USD | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|
Cash | 87.9m | 88.7m | 97.4m | 93.3m | 90.6m | 84.9m | 89.9m | 81.2m | 148.9m | |
Accounts Receivable | 113.2m | 121.1m | 123.7m | 119.1m | 116.6m | 142.6m | 4.8m | 118.3m | 102.5m | 94.1m |
Prepaid Expenses | 9.5m | 9.8m | 10.1m | 11.5m | 12.5m | 11.3m | 14.0m | 16.2m | ||
Inventories | 38.9m | 38.2m | 33.4m | 35.9m | 33.3m | 31.9m | 28.1m | 28.1m | 30.8m | 24.6m |
Annual
Quarterly
| USD | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|
Net Income | 81.1m | 113.2m | 124.6m | (700.0k) | 1.9m | 8.8m | (20.6m) | (28.9m) | (144.1m) | (39.5m) |
Depreciation and Amortization | 13.2m | 26.3m | 39.3m | 18.3m | 36.3m | 54.6m | 18.2m | 36.4m | 54.3m | 18.4m |
Inventories | 3.3m | 4.1m | 8.9m | 3.5m | 6.1m | 7.4m | 3.1m | 2.6m | 2.4m | |
Accounts Payable | 400.0k | 3.0m | (2.0m) | (8.4m) | (300.0k) | (8.1m) | (9.3m) | (11.3m) | (2.1m) | 300.0k |
| USD | FY, 2017 |
|---|---|
Revenue/Employee | 321.4k |
Debt/Equity | 0.3 x |
Debt/Assets | 0.2 x |
Financial Leverage | 1.6 x |
Myriad Genetics Acquisitions / Subsidiaries
| Company Name | Date | Deal Size |
|---|---|---|
| Myriad Women’s Health | May 29, 2018 | $408.6 m |
| Myriad Neuroscience | August 03, 2016 | $351.6 m |
| Sividon Diagnostics | May 31, 2016 | $56 m |
| Privatklinik Dr. Robert Schindlbeck | February 27, 2015 | $20.1 m |
| Crescendo Bioscience | February 04, 2014 | $270 m |
| Rules-Based Medicine | April 27, 2011 | $80 m |
| Javelin Pharmaceuticals | December 18, 2009 | $95 m |
| NaturNorth Technologies | April 10, 2008 | |
| AssureRx Canada, Ltd | ||
| Assurex Health, Inc. |
Myriad Genetics Revenue Breakdown
Myriad Genetics revenue breakdown by business segment: 7.2% from Pharmaceutical and Clinical Services and 92.8% from Molecular Diagnostic Testing
Myriad Genetics Cybersecurity Score
Myriad Genetics Environment, Social & Governance (ESG) Ratings
Myriad Genetics Online and Social Media Presence
6.3k Twitter followers
Myriad Genetics has 6.3k Twitter Followers. The number of followers has decreased 0.2% month over month and increased 1.4% quarter over quarter
Myriad Genetics's Trends
Twitter Engagement Stats for @myriadgenetics
17.3k
Tweets
874
Following
6.3k
Followers
17
Tweets last 30 days
1.8
Avg. likes per Tweet
94.1%
Tweets with engagement
Myriad Genetics Company Culture
Overall Culture
B
70/100
CEO Rating
D+
61/100
Compensation
B
74/100
Myriad Genetics News and Updates
June 04, 2021
Myriad Genetics CEO Paul J. Diaz to Present at Goldman Sachs 2021 Virtual Global Healthcare Conference
SALT LAKE CITY, June 04, 2021 (GLOBE NEWSWIRE) -- Paul J. Diaz, president and CEO of Myriad Genetics (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will discuss the company’s transformation plan and growth initiatives during a fireside chat at the Goldman Sachs 2021 Virtual Gl…
June 01, 2021
Myriad Genetics Completes the Sale of Myriad myPath® Melanoma, LLC, Laboratory to Castle Biosciences
SALT LAKE CITY, June 01, 2021 (GLOBE NEWSWIRE) -- On May 28, 2021, Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, completed the sale of its wholly-owned subsidiary, Myriad myPath, LLC, which owns the laboratory that offers the myPath Melanoma test, to Cas…
May 24, 2021
Myriad Genetics Signs Definitive Agreement to Sell Myriad RBM to Q2 Solutions
SALT LAKE CITY, May 24, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has signed a definitive agreement to sell Myriad RBM, Inc. to Q2 Solutions, a leading global clinical trial laboratory services organization…
May 20, 2021
Myriad Genetics Appoints Melissa Gonzales to Lead Women’s Health Business
New President Brings Proven Track Record in Women’s Health; Direct to Physician and Direct to Patient Commercial Expertise New President Brings Proven Track Record in Women’s Health; Direct to Physician and Direct to Patient Commercial Expertise
May 19, 2021
Myriad Genetics to Share New Data at 2021 ASCO Validating Personalized Breast Cancer Risk Assessments for Women of All Ancestries
Study Is First to Validate New Polygenic Risk Assessment for All; Company Aims to Improve Access and Reduce Disparities in Genetic Testing Study Is First to Validate New Polygenic Risk Assessment for All; Company Aims to Improve Access and Reduce Disparities in Genetic Testing
May 05, 2021
Myriad Genetics CEO Paul J. Diaz to Present at Bank of America Securities 2021 Virtual Health Care Conference
SALT LAKE CITY, May 05, 2021 (GLOBE NEWSWIRE) -- Paul J. Diaz, president and CEO of Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will discuss the company’s transformation plan and growth initiatives during a fireside chat at the Bank of America Securiti…
Myriad Genetics Blogs
June 16, 2021
My Myriad: Gwen Turner, Diversity, Equity, Inclusion, and Engagement
At Myriad Genetics, we’re proud to deliver clinically actionable genetic information in the areas of oncology, women’s health, and mental health.
The post My Myriad: Gwen Turner, Diversity, Equity, Inclusion, and Engagement appeared first on Myriad Genetics, Inc..
May 20, 2021
ASCO 2021 Preview: Making Breast Cancer Risk Assessment More Inclusive
We are already looking forward to one of the biggest cancer-focused conferences of the year: the annual meeting of the American
The post ASCO 2021 Preview: Making Breast Cancer Risk Assessment More Inclusive appeared first on Myriad Genetics, Inc..
May 04, 2021
Health. Illuminated.
Leading the Way to the Future of Genetic Testing and Precision Medicine Thirty years ago, Myriad Genetics played a pivotal role
The post Health. Illuminated. appeared first on Myriad Genetics, Inc..
April 21, 2021
Thank a Laboratory Professional This Week!
This week is Medical Laboratory Professionals Week, and that means the Myriad Genetics team is celebrating! Now in its 45th year, “Lab Week,” as it’s
The post Thank a Laboratory Professional This Week! appeared first on Myriad Genetics, Inc..
March 23, 2021
Boldly Going Exactly Where I Was Meant to Be!
Since joining Myriad Genetics two decades ago, I’ve had five different roles across various departments––and the company has nurtured my dream
The post Boldly Going Exactly Where I Was Meant to Be! appeared first on Myriad Genetics, Inc..
March 03, 2021
Join Us in Raising Awareness of Colorectal Cancer
You hear a lot about certain types of cancer. In fact, you can probably name some famous people who have had
The post Join Us in Raising Awareness of Colorectal Cancer appeared first on Myriad Genetics, Inc..
Myriad Genetics Frequently Asked Questions
When was Myriad Genetics founded?
Myriad Genetics was founded in 1991.
Who are Myriad Genetics key executives?
Myriad Genetics's key executives are Bryan Riggsbee, Paul J. Diaz and Patrick Burke.
How many employees does Myriad Genetics have?
Myriad Genetics has 2,600 employees.
What is Myriad Genetics revenue?
Latest Myriad Genetics annual revenue is $299.8 m.
What is Myriad Genetics revenue per employee?
Latest Myriad Genetics revenue per employee is $115.3 k.
Who are Myriad Genetics competitors?
Competitors of Myriad Genetics include Asuragen, Progenity and Foundation Medicine.
Where is Myriad Genetics headquarters?
Myriad Genetics headquarters is located at 320 Wakara Way, Salt Lake City.
Where are Myriad Genetics offices?
Myriad Genetics has offices in Salt Lake City, Austin, South San Francisco, Issy-les-Moulineaux and in 8 other locations.
How many offices does Myriad Genetics have?
Myriad Genetics has 13 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies